

**ANNOUNCEMENT**

**Services and Research Collaboration Agreement between CellResearch Corporation Pte Ltd and the University of Colorado School of Medicine.**

[Singapore – June 16, 2015] CellResearch Corporation Pte Ltd (“CRC”), a Singapore-based company that specializes in stem cell technology, has entered into a Services and Research Collaboration Agreement with the University of Colorado School Of Medicine (“SOM”) and ClinImmune Labs (“CIL”). SOM and CIL are part of the University of Colorado Anschutz Medical Campus, which have a US Federal Drug Agency (“US FDA”) licensed, cGMP stem cell/cord blood bank. The agreement is made via University Physicians, Inc., the fiscal and business agent for the University of Colorado School Of Medicine.

The Service and Research Collaboration Agreement has the objective of achieving US FDA approval for therapeutic products of Umbilical Cord Lining Membrane Progenitor/Stem cells. This first collaboration will focus on the development of CRC’s proprietary and patented **Cord Lining Mesenchymal Stem Cells for the Treatment of Diabetic Wounds**. Under the agreement, SOM and CIL will initially provide technical and clinical guidance for the production and testing of a cell bank of CRC’s mesenchymal stem cells. This will include the necessary preclinical and clinical testing needed by the US FDA for Clinical Phase I and II approval for the treatment of diabetic wounds.

Dr. Brian Freed, Professor at the Division of Allergy and Clinical Immunology of University of Colorado School of Medicine and Executive Director of ClinImmune Labs, will head the project. Dr. Freed is a leading expert in stem cell therapy, with over 30 years of experience and over 80 publications in the fields of stem cell banking and histocompatibility. Dr. Freed is also a diplomate of the American Board of Histocompatibility and Immunogenetics.

Gavin Tan, Group Chief Executive Officer of CellResearch Corporation said, “We are delighted to be able to work together with the University Of Colorado School Of Medicine, one of the world’s leaders in stem cell research and therapy. Chronic diabetic wounds are notoriously difficult to heal, we believe that this agreement is a key step towards our objective of providing an affordable and effective wound care solution for sufferers. This development is also an important move forward to allow cord lining stem cell therapy to treat other diseases”.

**About CellResearch Corporation Pte Ltd**

Founded in Singapore in 2002 by a group of clinician scientists and investors, CellResearch Corporation Pte Ltd (“CRC”) is the pioneer and global leader in Cord Lining Stem Cells for Stem Cell Regenerative Medicine and Therapy. Both an inventor and market leader in this space, CRC is at its core a Cord Lining Stem Cell Technology Asset Manager, with its main business lines comprising the banking of Cord Lining Stem Cells, development of cosmeceuticals in the form of their product, Calcim<sup>®</sup>, and advanced wound care, through their CorLinEx<sup>™</sup> developments.

CRE<sup>α</sup>TE A BETTER WORLD

CellResearch Corporation Pte Ltd • UEN 200208514E

137 Market Street • Unit 08-02 • Grace Global Raffles • Singapore 048943

Phone: +65 6444-9968 • Fax: +65 6722-4261 • Email: info@cellresearchcorp.com

CRC also owns one of the world's largest private skin, scar and keloid cell libraries which provides high quality primary cell strains, culture media and research service support to researchers and corporations worldwide. A company valuation of S\$639.7 million as of 2014 can be attributed to the impressive pace at which CRC has worked to obtain a vast range of patents in over 35 countries worldwide for their innovations and products.

CRC has formed commercial partnerships with conglomerates in the bio-medical industry such as Valeant Pharmaceuticals International Inc. ("Valeant"), a multinational speciality pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products. Valeant helps CRC launch some of its patented products into new markets. CRC's subsidiary is also in a strategic alliance with Singapore-listed company Cordlife Group Ltd ("Cordlife"), to provide human postnatal umbilical cord tissue storage services. Cordlife is a dominant market leader in the cord blood and tissue banking business in Singapore, and their alliance with CRC covers many Asian countries such as India, Hong Kong, Philippines and Malaysia. CRC's latest partnership with the University of Colorado School of Medicine also includes a synergistic relationship with the University's partner Caricord Inc. a US corporation that offers consumers cord blood banking services. The Californian-based company utilizes pharmaceutical grade, US FDA-licensed processing and storage practices and facilities located at the University of Colorado School of Medicine.

For more information, visit <http://www.cellresearchcorp.com/>

#### About University of Colorado School of Medicine/ClinImmune Labs

The University of Colorado School of Medicine is one of the top public urban research universities in the US educating currently more than 14,000 students on its comprehensive campus in downtown Denver and more than 3,000 students in its research and advanced health care programs at the Anschutz Medical Campus.

ClinImmune Labs is an academic enterprise of the Colorado School of Medicine with an FDA-licensed, cGMP stem cell/cord blood bank. ClinImmune Labs is a highly efficient academic business that integrates the highest quality laboratory services and products with its scholarly mission to contribute to the science of, and education about, stem cell therapy, histocompatibility and immunogenetics. ClinImmune Labs is accredited by the American Society for Histocompatibility and Immunogenetics ("ASHI"), the College of American Pathologists ("CAP"), the Clinical Laboratory Improvement Act ("CLIA"), the American Associations of Blood Banks ("AABB"), and the Foundation for Accreditation of Cellular Therapy ("FACT").